{"nctId":"NCT00684047","briefTitle":"Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis","startDateStruct":{"date":"2008-02"},"conditions":["Target Bleeding Site During Peripheral Vascular Surgery"],"count":239,"armGroups":[{"label":"FS Grifols Preliminary Part (I)","type":"EXPERIMENTAL","interventionNames":["Biological: FS Grifols"]},{"label":"FS Grifols Primary Part (II)","type":"EXPERIMENTAL","interventionNames":["Biological: FS Grifols"]},{"label":"Manual Compression Primary Part (II)","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Manual Compression"]}],"interventions":[{"name":"FS Grifols","otherNames":[]},{"name":"FS Grifols","otherNames":[]},{"name":"Manual Compression","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are male or female\n* Must be at least 3 years of age with no upper age limit (must be at least 18 years of age in Spain and United Kingdom)\n* Require an elective (non-emergency), open (non-laparoscopic; non-endovascular) peripheral vascular surgical procedure\n* Have hemoglobin ≥ 9.0 g/dL\n* Have platelet count \\> 70 x 10\\^3/mm\\^3\n* Required one peripheral vascular procedure involving either an arterial patch angioplasty or an arterial anastomosis utilizing polytetrafluoroethylene or Dacron grafts, according to the Investigator's (the surgeon's) selection:\n\n  1. Carotid endarterectomy requiring patch angioplasty\n  2. Carotid-subclavian bypass grafting\n  3. Axillo-femoral bypass grafting\n  4. Abdominal aortic aneurysm resection and graft replacement\n  5. Aorto-mesenteric bypass grafting\n  6. Aorto-celiac bypass grafting\n  7. Aorto-uni-iliac bypass grafting\n  8. Aorto-bi-iliac bypass grafting\n  9. Aorto-uni-femoral bypass grafting\n  10. Aorto-bi-femoral bypass grafting\n  11. Iliac aneurysm resection and graft replacement\n  12. Femoral aneurysm resection and graft replacement\n  13. Femoral-femoral bypass grafting\n  14. Femoral-popliteal bypass grafting\n  15. Renal arterial revascularization (bypass grafting)\n  16. Renal arterial revascularization (endarterectomy with patch angioplasty)\n  17. Popliteal artery revascularization (bypass grafting)\n  18. Popliteal artery revascularization (endarterectomy with patch angioplasty)\n  19. Femoral endarterectomy with patch angioplasty\n  20. Ilio-femoral bypass grafting\n* Intra-operative inclusion criterion:\n\n  * A Target bleeding site (TBS)can be identified according to the Investigator's judgment, and the TBS has a mild or moderate arterial bleeding according to the Investigator's judgment\n\nExclusion Criteria:\n\n* Weighed \\< 20 kg\n* Have a pre-operative (at Baseline Assessments) international normalized ratio ≥ 2.0\n* Have a pre-operative (at Baseline Assessments) activated partial thromboplastin time ratio ≥ 1.5\n* Have a pre-operative (at Baseline Assessments) serum creatinine \\> 2 times the upper limit of the normal range\n* Were undergoing a re-operative procedure on same arterial patch angioplasty or arterial anastomosis\n* Have an infection in the anatomical surgical area\n* Have a history of severe (e.g., anaphylactic) reactions to blood or any blood derived product\n* Unwilling to receive blood products\n* Have positive bleeding history\n* Female who was pregnant or nursing\n* Are known to abuse alcohol, opiates, psychotropic agents or other chemicals or drugs, or have done so within 12 months to the screening visit.\n* Are currently participating in another investigational drug or device clinical study, or have participated within 3 months to the screening visit.\n* Were previously included in this clinical trial (protocol number IG402)","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Efficacy Endpoint is Time to Hemostasis.","description":"The primary efficacy endpoint of the study is time to hemostasis (TTH), measured in minutes from the start of treatment application (TStart) at the TBS to the achievement of hemostasis at that site or to the end of the 10-minute observational period if hemostasis has not yet been achieved.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"71.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"28.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportions of Subjects Achieving Hemostasis","description":"The cumulative proportions of subjects who achieved hemostasis during the 10- minute observation period in Primary Part (II)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Treatment Failures","description":"The cumulative proportions of subjects who did not achieve hemostasis during the 10- minute observation period in Primary Part (II)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"28.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":187},"commonTop":["Procedural Pain","Nausea","Constipation","Hypotension","Vomiting"]}}}